Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.
Amir Momeni BoroujeniWissam DahoudChad M VanderbiltSarah ChiangRajmohan MuraliEric V Rios-DoriaKaled M AlektiarCarol AghajanianNadeem R Abu-RustumMarc LadanyiLora H EllensonBritta WeigeltRobert A SoslowPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
TP53-mutated endometrial carcinomas display clinical and molecular similarities across histologic subtypes. Our data provide evidence to suggest performance of ERBB2 assessment in all TP53-mutated endometrial carcinomas. Given the distinct clinical features of serous carcinomas, histologic classification continues to be relevant.